ZYDUSLIFE - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.0
| Stock Code | ZYDUSLIFE | Market Cap | 89,746 Cr. | Current Price | 892 ₹ | High / Low | 1,059 ₹ |
| Stock P/E | 19.1 | Book Value | 215 ₹ | Dividend Yield | 1.23 % | ROCE | 30.6 % |
| ROE | 31.1 % | Face Value | 1.00 ₹ | DMA 50 | 910 ₹ | DMA 200 | 928 ₹ |
| Chg in FII Hold | -0.11 % | Chg in DII Hold | 0.12 % | PAT Qtr | 343 Cr. | PAT Prev Qtr | 1,157 Cr. |
| RSI | 43.3 | MACD | 4.65 | Volume | 10,00,761 | Avg Vol 1Wk | 11,02,968 |
| Low price | 836 ₹ | High price | 1,059 ₹ | PEG Ratio | 0.26 | Debt to equity | 0.35 |
| 52w Index | 25.2 % | Qtr Profit Var | -27.2 % | EPS | 46.2 ₹ | Industry PE | 30.1 |
📈 Optimal Buy Price: 885 ₹ – 895 ₹
🎯 Profit Exit Levels: 915 ₹ – 935 ₹
🛡️ Stop-Loss: 870 ₹
⏳ Intraday Exit Guidance:
If already holding, consider exiting if RSI dips below 42 with rising volume or if price fails to sustain above 892 ₹. Momentum exits are near 915–935 ₹; book profits if volume fades or MACD weakens intraday.
---
Positive
✔️ Strong ROCE (30.6%) and ROE (31.1%) indicate excellent efficiency
✔️ EPS at 46.2 ₹ supports valuation stability
✔️ PEG ratio 0.26 suggests undervaluation relative to growth
✔️ Price near DMA 50 (910 ₹) and DMA 200 (928 ₹), offering technical support
✔️ Dividend yield of 1.23% adds investor confidence
Limitation
⚠️ PAT declined sharply (343 Cr. vs 1,157 Cr.), showing earnings pressure
⚠️ RSI at 43.3 indicates weak momentum, near oversold zone
⚠️ Volume slightly below weekly average, limiting intraday strength
⚠️ Debt-to-equity ratio at 0.35, moderate leverage risk
⚠️ FII holdings decreased (-0.11%), showing reduced foreign confidence
Company Negative News
❌ Quarterly profit contraction (-27.2%)
❌ Decline in foreign institutional holdings
Company Positive News
✅ DII holdings increased (+0.12%), showing domestic support
✅ EPS remains strong despite profit decline
✅ Dividend yield attractive compared to peers
Industry
🏭 Industry PE at 30.1, moderately higher than company’s 19.1 valuation
📊 Pharma sector remains resilient with steady demand
📈 Peers trade at higher valuations, giving ZYDUSLIFE relative value advantage
Conclusion
ZYDUSLIFE is a strong intraday candidate with robust fundamentals and attractive valuation. However, weak momentum and profit contraction limit upside. Best suited for disciplined intraday trades with tight stop-losses and profit booking near resistance levels.
Would you like me to extend this into a swing-trade HTML report with sector overlays (Sun Pharma, Cipla, Dr. Reddy’s) so you can benchmark ZYDUSLIFE’s medium-term positioning against pharma peers?